Rallybio (RLYB) Current Deferred Revenue (2024 - 2025)
Rallybio (RLYB) posted Current Deferred Revenue of $212000.0 for Q4 2025, down 50.0% sequentially from $424000.0 in Q3 2025, and down 75.0% YoY from $848000.0 in Q4 2024.
Rallybio (RLYB) Current Deferred Revenue (2024 - 2025) Analysis & Trends
Rallybio has reported Current Deferred Revenue for 2 years, with the latest figure at $212000.0 in Q4 2025.
- Quarterly Current Deferred Revenue fell 75.0% year-over-year to $212000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $212000.0 (down 75.0% YoY) and the FY2025 annual result came in at $212000.0, down 75.0% from the prior year.
- Current Deferred Revenue declined to $212000.0 in Q4 2025 per RLYB's latest filing, from $424000.0 in the prior quarter.
- Over five years, Current Deferred Revenue peaked at $1.2 million in Q2 2024 and troughed at $212000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 212,000.00 |
| Sep 30, 2025 | 424,000.00 |
| Jun 30, 2025 | 636,000.00 |
| Mar 31, 2025 | 848,000.00 |
| Dec 31, 2024 | 848,000.00 |
| Sep 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.20 Mn |